The aggregation of a polypeptide chain into amyloid fibrils and their accumulation and
deposition into insoluble plaques and intracellular inclusions is the hallmark of several …

Background Intraocular inflammation is an uncommon but potentially vision-threatening
adverse event related to anti-VEGF therapy. This is of increasing importance given both the …

To ensure the stability of biologicals over their entire shelf-life, non-ionic surface-active
compounds (surfactants) are added to protect biologics from denaturation and particle …

Protein stability against aggregation is a major quality concern for the production of safe and
effective biopharmaceuticals. Amongst the different drivers of protein aggregation …

Among many other applications, polysorbates (PSs) are used as the most common
surfactants in biopharmaceutical products in particular to protect proteins against interfacial …

Intravitreal injections have become the most commonly performed intraocular treatments
worldwide. Because intravitreal injections may induce severe adverse events, such as …

Protein pharmaceuticals have become a significant class of marketed drug products and are
expected to grow steadily over the next decade. Development of a commercial protein …

A host of new technologies are under development to improve the quality and reproducibility
of cryoelectron microscopy (cryoEM) grid preparation. Here we have systematically …

The safety and efficacy of protein pharmaceuticals depend not only on biological activity but
also on purity levels. Impurities may be process related because of limitations in …

Protein aggregation is a major challenge in the development of biopharmaceuticals. As the
pathways of aggregation are manifold, good understanding of the mechanisms behind is …